Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 823 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Echocardiograms Clear all
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Ulixertinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

Sex and Obesity: Effects on Heart Failure Study

NCT00776035
View directory record Official record
Conditions
Obesity, Heart Failure
Interventions
PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose
Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart Ultrasound by Emergency Medicine Residents as an Estimate of Heart Function

NCT05506059
View directory record Official record
Conditions
Stroke Volume, Cardiovascular Diseases
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 8, 2026, 5:47 PM EDT
Terminated Not applicable Interventional Results available

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

NCT00894179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson and atropine
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 8, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

NCT05174351
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
beta blocker discontinuation
Other
Lead sponsor
UConn Health
Other
Eligibility
50 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 8, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

NCT02880137
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Perflutren Lipid Microsphere, RTMPE
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 8, 2026, 5:47 PM EDT
Withdrawn No phase listed Observational

Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography

NCT00774657
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 8, 2026, 5:47 PM EDT
Terminated No phase listed Observational

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

NCT02300870
View directory record Official record
Conditions
Heart Transplantation
Interventions
Optison
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Recruiting No phase listed Observational

DELINEATE-Prospective

NCT07197736
View directory record Official record
Conditions
Valve Disease, Aortic, Mitral Regurgitation (MR), Aortic Stenosis, Valvular Heart Disease, Tricuspid Regurgitation (TR), Aortic Regurgitation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging

NCT02415244
View directory record Official record
Conditions
Spinal Cord, Epidural
Interventions
TEE
Procedure
Lead sponsor
Kenichi Ueda
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

NCT00730964
View directory record Official record
Conditions
Echocardiography
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 8, 2026, 5:47 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging
Other · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Real Time 3-Dimensional Stress Echocardiography

NCT00001886
View directory record Official record
Conditions
Coronary Disease
Interventions
Real time 3-dimensional stress echocardiography
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 8, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
View directory record Official record
Conditions
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
180 Days to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
107
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 84 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Real World Expanded Multicenter Study of the MitraClip® System (REALISM)

NCT01931956
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
MitraClip® implant
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
38
States / cities
Los Angeles, California • Mountain View, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

NCT00625365
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
DEFINITY®
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Newark, Delaware • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 8, 2026, 5:47 PM EDT
Completed No phase listed Observational

Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy

NCT02195999
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram
Other
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 15 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 8, 2026, 5:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.

NCT04447365
View directory record Official record
Conditions
Gut Microbiome
Interventions
device interrogation
Diagnostic Test
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

NCT03842228
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 5:47 PM EDT